Sandbox/AL: Difference between revisions

Revision as of 17:06, 8 July 2014

Argatroban
Argatroban^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Overview

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have or at risk for developing HIT.

Argatroban is given intravenously. Argatroban is metabolized in the liver and has a half life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).

It is manufactured by GlaxoSmithKline.

FDA Package Insert

ARGATROBAN injection, solution

Reference

Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. PMID 16148288.

External links

GlaxoSmithKline's website on argatroban

@@ Line 1: / Line 1: @@
 __NOTOC__
+{{Argatroban}}
+{{CMG}}; {{AE}} {{JH}}
-{{Antithrombin III}}
+==Overview==
-{{CMG}}; {{AE}} {{JH}}
+'''Argatroban''' is an [[anticoagulant]] that is a small molecule [[direct thrombin inhibitor]].  In 2000, argatroban was licensed by the [[Food and Drug Administration]] (FDA) for prophylaxis or treatment of [[thrombosis]] in patients with [[heparin-induced thrombocytopenia|heparin-induced thrombocytopenia (HIT)]].  In 2002, it was approved for use during [[Angioplasty|percutaneous coronary interventions]] in patients who have or at risk for developing [[HIT]].
-'''''For patient information, click <u>[[Antithrombin III (patient information)|here]]'''''</u>.
+Argatroban is given intravenously.  Argatroban is metabolized in the [[liver]] and has a half life of about 50 minutes.  It is monitored by [[PTT]].  Because of its hepatic metabolism, it may be used in patients with [[renal dysfunction]].  (This is in contrast to [[lepirudin]], a [[direct thrombin inhibitor]] that is primarily renally cleared).
-==Overview==
+It is manufactured by [[GlaxoSmithKline]].
 ==Category==
-==US Brand Names==
+Anticoagulants; Direct Thrombin Inhibitor
-'''THROMBATE III'''<sup>®</sup>
 ==FDA Package Insert==
-'''| [[Antithrombin III indications and usage|Indications and Usage]]'''
+====ARGATROBAN injection, solution====
-'''| [[Antithrombin III dosage and administration|Dosage and Administration]]'''
-'''| [[Antithrombin III dosage forms and strengths|Dosage Forms and Strengths]]'''
+'''  [[Argatroban indications and usage|Indications and Usage]]'''
-'''| [[Antithrombin III contraindications|Contraindications]]'''
+'''| [[Argatroban dosage and administration|Dosage and Administration]]'''
-'''| [[Antithrombin III warnings|Warnings and Precautions]]'''
+'''| [[Argatroban dosage forms and strengths|Dosage Forms and Strengths]]'''
-'''| [[Antithrombin III adverse reactions|Adverse Reactions]]'''
+'''| [[Argatroban contraindications|Contraindications]]'''
-'''| [[Antithrombin III drug interactions|Drug Interactions]]'''
+'''| [[Argatroban warnings and precautions|Warnings and Precautions]]'''
-'''| [[Antithrombin III use in specific populations|Use in Specific Populations]]'''
+'''| [[Argatroban adverse reactions|Adverse Reactions]]'''
-'''| [[Antithrombin III overdosage|Overdosage]]'''
+'''| [[Argatroban drug interactions|Drug Interactions]]'''
-'''| [[Antithrombin III description|Description]]'''
+'''| [[Argatroban use in specific populations|Use in Specific Populations]]'''
-'''| [[Antithrombin III clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Argatroban overdosage|Overdosage]]'''
-'''| [[Antithrombin III nonclinical toxicology|Nonclinical Toxicology]]'''
+'''| [[Argatroban description|Description]]'''
-'''| [[Antithrombin III clinical studies|Clinical Studies]]'''
+'''| [[Argatroban clinical pharmacology|Clinical Pharmacology]]'''
-'''| [[Antithrombin III how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[Argatroban nonclinical toxicology|Nonclinical Toxicology]]'''
-'''| [[Antithrombin III patient counseling information|Patient Counseling Information]]'''
+'''| [[Argatroban clinical studies|Clinical Studies]]'''
-'''| [[Antithrombin III labels and packages|Labels and Packages]]'''
+'''| [[Argatroban how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[Argatroban patient counseling information|Patient Counseling Information]]'''
+'''| [[Argatroban labels and packages|Labels and Packages]]'''
+==Reference==
-==Mechanism of Action==
+* Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. ''[[N Engl J Med]]'' 2005;353:1028-40. PMID 16148288.
-==References==
+==External links==
-{{Cite web  | last =  | first =  | title = THROMBATE III (ANTITHROMBIN III) KIT [GRIFOLS USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2a9f856-3ef7-8da4-920c-f738e4f1f7d7 | publisher =  | date =  | accessdate = 7 March 2014 }}
+*[http://www.argatroban.com GlaxoSmithKline's website on argatroban]
-{{Reflist|2}}
+{{Antithrombotics}}
+[[Category:Anticoagulants]]
+[[Category:Cardiology]]
+[[Category:Cardiovascular Drugs]]
 [[Category:Drugs]]
+[[Category:Hematology]]